Correlation of FC Gamma RIIIA Receptor Response in Patients With Waldenstrom's Macroglobulinemia
Part of paid clinical trials in Boston, Massachusetts.
- Sponsor
- Dana-Farber Cancer Institute
- Study ID
- NCT00142155
- Status
- Completed
Conditions
- Waldenstrom's Macroglobulinemia
Eligibility Criteria
- Sex
- ALL
- Age
- 30 Years - 90 Years
- Healthy Volunteers
- Not accepted
Interventions
- Rituximab — DRUG
- monoclonal antibodies — DRUG
Study Details
The purpose of this study is to determine if the type of Fc gamma RIIIa receptor that a particular patient's immune cells possess influences how they respond to rituximab and other monoclonal antibodies.
Key Dates
- Start date
- Jan 31, 2002
- Status verified
- Jun 2011
- Primary completion
- Mar 31, 2007
- Completion
- Mar 31, 2007
Study Design
- Enrollment
- 300 participants (estimated)
Locations (1)
| Facility | City | State | ZIP | Site coordinators |
|---|---|---|---|---|
| Dana-Farber Cancer Institute | Boston | Massachusetts | 02115 | - |
Find similar trials in Boston, MA
By research site